List of Excipients in Branded Drug COSOPT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	COSOPT	dorzolamide hydrochloride and timolol maleate	17478-605	BENZALKONIUM CHLORIDE
Akorn	COSOPT	dorzolamide hydrochloride and timolol maleate	17478-605	HYDROXYETHYL CELLULOSE
Akorn	COSOPT	dorzolamide hydrochloride and timolol maleate	17478-605	MANNITOL
Akorn	COSOPT	dorzolamide hydrochloride and timolol maleate	17478-605	SODIUM CITRATE
Akorn	COSOPT	dorzolamide hydrochloride and timolol maleate	17478-605	SODIUM HYDROXIDE
Akorn	COSOPT	dorzolamide hydrochloride and timolol maleate	17478-605	WATER

COSOPT Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

COSOPT is a fixed-dose ophthalmic solution containing dorzolamide hydrochloride and timolol maleate for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its excipient strategy is relatively simple: aqueous buffering, viscosity control, tonicity adjustment, pH control, and antimicrobial preservation in the multidose product. The main commercial opportunity is not a new active ingredient. It is differentiated delivery through preservative-free packaging, improved ocular tolerability, stability control, manufacturing efficiency, and supply-chain reliability.

COSOPT is marketed in two principal formats:

Product	Active ingredients	Key excipient distinction	Commercial role
COSOPT ophthalmic solution	Dorzolamide hydrochloride 2% and timolol maleate 0.5%	Contains benzalkonium chloride preservative	Multidose bottle
COSOPT PF ophthalmic solution	Dorzolamide hydrochloride 2% and timolol maleate 0.5%	Preservative-free	Single-use container

The branded product is associated with Merck Sharp & Dohme, while generic versions are available in the United States. The active pharmaceutical ingredient combination is mature, and commercial differentiation depends heavily on formulation execution, packaging, regulatory status, and channel economics.

What excipients are used in COSOPT?

The conventional COSOPT formulation contains benzalkonium chloride, sodium citrate, hydroxyethyl cellulose, mannitol, sodium hydroxide, and purified water or water for injection as applicable to the manufacturing process. The precise inactive-ingredient listing and concentrations should be taken from the current approved labeling and regulatory database for the target market.

Excipient or excipient class	Function in COSOPT-type formulation	Commercial and technical relevance
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but creates ocular-surface tolerability concerns
Sodium citrate	Buffering agent	Supports pH control and active-ingredient stability
Hydroxyethyl cellulose	Viscosity modifier	Extends ocular residence time and controls drop characteristics
Mannitol	Tonicity-adjusting agent and formulation stabilizer	Helps manage osmolality and product feel
Sodium hydroxide	pH adjuster	Allows final pH adjustment during batch release
Purified water	Vehicle	Determines bulk solution quality and microbial-control burden

The COSOPT PF formulation removes benzalkonium chloride and uses single-dose containers. The preservative-free format shifts the control strategy from chemical preservation to sterile manufacturing, container integrity, unit-dose handling, and package protection.

How does the COSOPT formulation work?

COSOPT combines two active mechanisms in one ophthalmic dosage form. Dorzolamide inhibits carbonic anhydrase II and reduces aqueous humor production. Timolol, a beta-adrenergic blocker, also reduces aqueous humor production. The formulation must keep both active ingredients chemically stable and physically compatible in a sterile aqueous vehicle.

Hydroxyethyl cellulose is commercially important because it can increase viscosity and ocular residence time without converting the product into a gel. Excessive viscosity, however, can produce blurred vision, poor drop formation, or inconsistent dosing. The target is a narrow balance between retention on the ocular surface and acceptable patient handling.

The buffer system must maintain a pH compatible with active-ingredient stability, preservative performance, container compatibility, and patient comfort. Mannitol supports osmolality control. Sodium hydroxide is used for final pH adjustment rather than as a principal therapeutic excipient.

What is the difference between COSOPT and COSOPT PF excipients?

The primary difference is the presence or absence of benzalkonium chloride.

COSOPT multidose formulation

The multidose formulation uses benzalkonium chloride to control microbial growth after repeated bottle opening. This design supports a conventional bottle presentation and lower packaging complexity. Its disadvantages include potential ocular-surface irritation, preservative exposure over chronic treatment, and compatibility requirements involving the bottle, cap, dropper tip, and closure system.

COSOPT PF preservative-free formulation

COSOPT PF removes the preservative and uses single-dose containers. This design reduces chronic exposure to benzalkonium chloride and may be commercially attractive for patients with ocular-surface disease, dry eye, frequent topical therapy, or intolerance to preserved products.

The preservative-free format creates other costs. It requires sterile unit-dose filling, higher packaging consumption, more complex logistics, and greater waste per administered dose. Unit-dose systems also require strong container-closure integrity and robust protection against evaporation, contamination, and extractables.

Attribute	COSOPT	COSOPT PF
Preservative	Benzalkonium chloride	None
Package	Multidose bottle	Single-dose containers
Manufacturing burden	Conventional sterile multidose production	Higher unit-dose filling and packaging burden
Ocular-surface positioning	Standard preserved product	Preservative-free positioning
Packaging cost	Lower per administered dose	Higher
Differentiation potential	Limited	Higher
Main technical risk	Preservative tolerability and compatibility	Sterility, closure integrity, and unit-dose usability

What excipient strategy offers the strongest commercial opportunity?

The strongest opportunity is a preservative-free, patient-friendly formulation supported by efficient unit-dose packaging. Replacing benzalkonium chloride is not a simple excipient substitution. It changes the microbiological control strategy and may require a new drug application, supplemental approval, or abbreviated regulatory pathway depending on the jurisdiction and formulation relationship.

A commercial excipient strategy should prioritize five objectives:

1. Maintain dorzolamide and timolol stability throughout shelf life.
2. Preserve acceptable pH, osmolality, viscosity, and drop size.
3. Avoid ocular-surface irritancy associated with chronic preservative exposure.
4. Reduce sterile manufacturing and packaging cost.
5. Create a defensible product profile without introducing unnecessary formulation complexity.

Potential excipient and delivery approaches include:

• Preservative-free aqueous solution in unit-dose containers.
• Low-preservative or alternative-preservative multidose systems, subject to regulatory acceptance.
• Improved hydroxyethyl cellulose grades for consistent viscosity and drop formation.
• Polymer systems that increase residence time without materially increasing blur.
• Low-extractables packaging for chronic ophthalmic use.
• Container systems that provide multidose preservative-free delivery.
• Unit-dose formats using recyclable or lower-material packaging.
• Packaging designed for easier administration by elderly patients with reduced dexterity.

The commercial value of each approach depends on clinical differentiation, reimbursement, manufacturing cost, and the ability to obtain regulatory approval without creating bioequivalence or therapeutic-equivalence uncertainty.

What formulation patents protect COSOPT-related products?

COSOPT’s core commercial protection is no longer based primarily on a new-excipient patent position. The active ingredients and fixed-dose combination are mature, and generic dorzolamide hydrochloride/timolol maleate ophthalmic products have entered the U.S. market.

Excipient-related protection can still arise through:

• Preservative-free container systems.
• Multidose dispensing mechanisms.
• Specific viscosity ranges.
• Defined pH and osmolality windows.
• Stabilized aqueous compositions.
• Manufacturing processes that reduce degradation products.
• Container-closure combinations.
• Unit-dose packaging configurations.
• Methods for treating patients who cannot tolerate preserved ophthalmic products.

These rights are often narrower than composition-of-matter patents and may be difficult to enforce against products using different excipient concentrations, packaging, or manufacturing methods. Their value depends on claim scope, enablement, prosecution history, freedom-to-operate analysis, and whether the claims cover commercially necessary product attributes.

A company seeking differentiated COSOPT technology should focus on claims tied to measurable product performance, not only a list of conventional excipients. Examples include a defined stability profile, a controlled viscosity range, a specific preservative-free delivery system, or a validated container-closure architecture.

What is the FDA regulatory status of COSOPT?

COSOPT is an FDA-approved ophthalmic solution for reducing elevated intraocular pressure. The reference product is associated with NDA 020597. COSOPT PF is a preservative-free presentation associated with a separate FDA approval pathway and labeling history. Current status should be verified against the FDA Drugs@FDA database and the most recent prescribing information before a regulatory or investment decision.[1]

The formulation is a sterile ophthalmic drug product. Key regulatory controls include:

• Sterility assurance.
• Particulate control.
• Assay and related substances.
• pH and osmolality.
• Viscosity.
• Drop size and delivered volume.
• Preservative content and effectiveness for multidose products.
• Container-closure integrity.
• Extractables and leachables.
• In-use stability.
• Microbial limits and process controls.

The FDA Inactive Ingredient Database can support excipient precedent analysis, but database listing does not establish automatic approval for a new concentration, route, dosage form, or product design.[2]

What is the Orange Book and generic status of COSOPT?

COSOPT is a legacy small-molecule ophthalmic product with generic competition. The relevant U.S. regulatory questions are whether the proposed generic references the listed drug, whether an ANDA has been approved, whether an applicant has submitted Paragraph IV certifications, and whether any listed patents or regulatory exclusivities remain commercially material.

For a mature product such as COSOPT, the major barriers are usually technical and commercial rather than basic active-ingredient exclusivity. These barriers include:

• Demonstrating pharmaceutical equivalence.
• Matching solution properties and delivered dose.
• Establishing sterility and preservative effectiveness.
• Managing ophthalmic bioequivalence requirements.
• Securing reliable supply of both active ingredients.
• Reproducing container performance.
• Obtaining approval for preservative-free or novel multidose presentations.

Paragraph IV litigation risk is generally more relevant to later-added formulation, packaging, or method-of-use patents than to the original fixed-dose combination. Orange Book listings and litigation records must be reviewed by product and jurisdiction because patent status can change through expiration, disclaimer, litigation, or delisting.[3]

When does COSOPT lose exclusivity?

The original active-ingredient and combination exclusivity period for COSOPT has expired, and generic products are commercially available in the United States. No current commercial strategy should assume that the original COSOPT formulation has meaningful market exclusivity.

The relevant distinction is between:

• Original product exclusivity, which is historical for COSOPT.
• Patent protection covering a specific formulation or device.
• Regulatory exclusivity for a later presentation.
• Market protection created by manufacturing complexity or limited competitor supply.

A preservative-free version may obtain commercial differentiation without creating durable exclusivity. The product could still face generic or authorized-generic competition unless the sponsor establishes enforceable patent claims, regulatory barriers, superior distribution, or a recognized clinical advantage.

What generic entry risks exist for COSOPT?

Generic entry risk is high for the conventional multidose formulation because the product uses established active ingredients and common ophthalmic excipients. Price competition can be substantial when several ANDA-approved products are available.

Risk is lower, but not eliminated, for preservative-free presentations. The main barriers are:

• Unit-dose sterile filling capacity.
• Container-closure validation.
• Packaging cost.
• In-use and stability data.
• Demonstration of equivalent delivered dose.
• Complex supply-chain management.
• Lower gross margin than conventional multidose products.

A generic manufacturer that can match the reference product’s solution properties while reducing packaging cost may compete effectively. A manufacturer that improves tolerability but materially increases cost may require premium reimbursement or a targeted specialty channel.

Which companies can capture COSOPT excipient opportunities?

The opportunity spans several supplier groups rather than a single pharmaceutical company.

Excipient suppliers

Suppliers of ophthalmic-grade cellulose polymers, citrate buffers, tonicity agents, and alternative preservative technologies can pursue qualified-supplier status. The strongest commercial propositions are consistent low-bioburden material, low endotoxin, tight viscosity control, and global regulatory support.

Contract development and manufacturing organizations

CDMOs with sterile ophthalmic filling, unit-dose packaging, and container-closure testing can support private-label, generic, and lifecycle-management programs. Capacity for preservative-free ophthalmic manufacturing is strategically more valuable than ordinary liquid filling capacity.

Packaging companies

Companies supplying multidose preservative-free dispensers, low-extractables polymers, unit-dose blow-fill-seal systems, and patient-friendly administration devices can capture value without owning the drug formulation.

Generic drug manufacturers

Generic companies can compete through lower-cost conventional solutions or differentiated preservative-free products. A reliable supply of dorzolamide hydrochloride and timolol maleate remains critical because ophthalmic shortages can affect market share rapidly.

How strong is the COSOPT patent estate?

The original COSOPT patent estate has limited strategic strength because the product is mature and generic competition exists. The stronger protection opportunities are incremental and formulation-specific.

Protection type	Strategic strength	Main limitation
Original active-ingredient protection	Low for current commercial strategy	Historical expiration and generic entry
Fixed-dose combination claims	Low to moderate	Potentially expired or vulnerable to established generic pathways
Preservative-free formulation claims	Moderate	Narrow scope and design-around risk
Container and dispensing patents	Moderate	Enforcement depends on device-specific claims
Manufacturing-process patents	Moderate	Difficult to detect infringement and may not block all competitors
Method-of-use patents	Low to moderate	Prescribing and enforcement limitations
Trade secrets and process know-how	Moderate	Useful for quality and yield, but not market exclusivity

Patent value is highest when the formulation, packaging system, and manufacturing process are integrated into a product that competitors cannot easily reproduce at comparable cost.

What is the commercial outlook for COSOPT excipients?

The largest near-term opportunity is lifecycle management of preservative-free dorzolamide/timolol therapy. Demand is supported by chronic glaucoma treatment, the aging population, polypharmacy, and concern about ocular-surface tolerability from long-term topical therapy.

Revenue exposure is concentrated in the product owner, generic manufacturers, excipient suppliers, sterile filling contractors, and packaging vendors. Publicly reported revenue is generally not isolated for COSOPT or its excipients because companies report ophthalmology products within broader business segments.

Commercial attractiveness can be ranked as follows:

1. Preservative-free unit-dose manufacturing and packaging.
2. Multidose preservative-free dispensing systems.
3. Ophthalmic-grade viscosity modifiers with tight lot control.
4. Low-extractables container systems.
5. Process technologies that improve sterile yield and reduce fill-finish cost.
6. Alternative preservative systems for multidose products.
7. Conventional commodity excipients.

The most defensible opportunity is a complete platform combining formulation, sterile processing, container closure, and regulatory documentation. A commodity excipient alone is less likely to create durable value unless it solves a documented stability, tolerability, or manufacturing problem.

Key Takeaways

• COSOPT uses a conventional sterile aqueous formulation based on buffering, viscosity control, tonicity adjustment, pH control, and preservation.
• Benzalkonium chloride is the principal differentiating excipient in the conventional multidose product.
• COSOPT PF removes the preservative and shifts the burden to sterile unit-dose manufacturing and container-closure performance.
• The original COSOPT exclusivity position is mature, and generic competition is established.
• The strongest commercial opportunities involve preservative-free delivery, ophthalmic-grade polymers, low-extractables packaging, and high-yield sterile manufacturing.
• Formulation and device patents can support differentiation, but they are generally narrower and more vulnerable to design-around than original active-ingredient patents.
• The principal investment risk is not excipient availability. It is achieving a clinically acceptable, regulatorily approvable, cost-efficient product that can compete against generic pricing.

FAQs

Is benzalkonium chloride present in COSOPT?

Yes. Conventional COSOPT ophthalmic solution contains benzalkonium chloride as a preservative. COSOPT PF is designed without benzalkonium chloride and is supplied in a preservative-free format.

Can COSOPT be reformulated with another preservative?

Potentially, but changing the preservative can affect antimicrobial effectiveness, ocular tolerability, active-ingredient stability, packaging compatibility, and regulatory comparability. The change would require formulation development and supporting regulatory data.

Is hydroxyethyl cellulose important to COSOPT performance?

Yes. Hydroxyethyl cellulose controls viscosity and can increase ocular residence time. Its concentration, substitution profile, grade, and lot-to-lot consistency can affect drop size, patient comfort, visual blur, and delivered dose.

Are COSOPT excipients patentable?

Specific compositions, concentration ranges, preservative-free systems, dispensing devices, packaging configurations, and manufacturing processes may be patentable if they meet novelty, inventive-step, enablement, and other applicable legal standards. Conventional excipients used in routine concentrations generally provide weak standalone patent positions.

Is COSOPT PF more commercially defensible than conventional COSOPT?

COSOPT PF has greater differentiation potential because it addresses preservative exposure and uses a distinct packaging format. Its defensibility remains limited unless supported by enforceable formulation or device claims, reliable supply, strong physician adoption, or a measurable tolerability advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. Merck Sharp & Dohme LLC. (n.d.). COSOPT and COSOPT PF prescribing information. U.S. Food and Drug Administration labeling repository.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.